BioClinica Optimizer launched for clinical supply planning and management

BioClinica™, Inc., (NASDAQ: BIOC), a global provider of clinical trial management services, today announced the launch of BioClinica Optimizer, a breakthrough for clinical supply planning and management that it believes has the potential to transform clinical trial supply forecasting and management. BioClinica Optimizer is a new product that combines and enhances the features of tcVisualize and tcOptimizer developed by Tourtellotte Solutions, which was acquired by BioClinica in September 2009. Allowing a customer to move beyond the current environment of spreadsheets and manual tools to plan and analyze clinical supply chains programmatically, BioClinica Optimizer integrates planning and feedback loops with other eClinical technologies.

“As the complexity of clinical trials continues to increase, it is imperative that accurate clinical supply planning -- coupled with rigorous tracking -- be a standard part of the process”

“BioClinica now offers the premiere eClinical solution available to help our customers plan, forecast and optimize their clinical trials,” said Mark Weinstein, CEO of BioClinica, Inc. “Optimizer provides customers the ability to streamline this vital process, potentially saving them hundreds of thousands of dollars per trial. This enhanced product is indicative of the types of services BioClinica strives to offer our customers, providing access to the highest quality tools and experience to help them maximize productivity and results. We believe BioClinica Optimizer sets a new benchmark for the planning of clinical studies.”

BioClinica Optimizer, including the original versions, has achieved successful results in hundreds of clinical trials across the globe, with four of the top ten pharmaceutical companies already using BioClinica’s clinical supply forecasting solutions. For example, in a recent trial involving 10 countries and 150 sites, Optimizer enabled the customer to save over $1.2M in supplies.

“As the complexity of clinical trials continues to increase, it is imperative that accurate clinical supply planning -- coupled with rigorous tracking -- be a standard part of the process,” said Ed Tourtellotte, VP of Product Innovation for BioClinica. “Many trials today are simply too complex and expensive to forecast without simulation. Though savings in materials and logistics can be substantial, the real win is to foresee and prevent stock-outs. Running out of critical supplies requires emergency shipments or catastrophically can even risk an entire trial, potentially costing both time and millions of dollars. Based upon the successes that our customers have had thus far, we can say with confidence that our new Optimizer product provides the optimal supply forecasting solution.”